[Form 4] Acadia Pharmaceuticals Inc. Insider Trading Activity

Rhea-AI Filing Summary

Mark C. Schneyer, EVP and Chief Financial Officer of Acadia Pharmaceuticals (ACAD), reported the sale of 22,000 shares of the issuer's common stock on 08/18/2025 at a weighted-average price of $25.1829 per share, with sale prices in the range $25.06 to $25.28. Following the reported disposition, Mr. Schneyer beneficially owned 40,130 shares. The Form 4 discloses the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. The filing was signed on behalf of the reporting person by an attorney-in-fact on 08/19/2025.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating pre-planned trades and reduced appearance of opportunistic insider timing
• Filing provides weighted-average price and price range with an undertaking to supply per-price quantities on request, showing transparency

Negative

• Reporting person disposed of 22,000 shares, reducing insider ownership to 40,130 shares which may be viewed negatively by some investors

Insights

Securities Analyst

TL;DR: Routine officer stock sales under a 10b5-1 plan; not an operational disclosure and likely neutral for ACAD's near-term fundamental outlook.

The Form 4 documents a pre-planned disposition of 22,000 common shares by the CFO executed under a Rule 10b5-1 plan, with a disclosed weighted-average price of $25.1829 and reported price range $25.06 to $25.28. Reporting that the trade was pursuant to a 10b5-1 plan reduces concerns about opportunistic timing, as these plans establish pre-set trading instructions. The filing also shows the reporting person retains 40,130 shares after the sale, which remains a modest ownership position relative to typical executive holdings. This disclosure is procedural and does not present new operational or financial information about Acadia Pharmaceuticals.

Corporate Governance Expert

TL;DR: Proper disclosure and plan usage indicate governance compliance; the transaction itself is routine and not materially transformative.

The Form 4 explicitly states the trades were covered by a 10b5-1 trading plan adopted May 19, 2025, which provides an affirmative defense against insider trading claims if implemented correctly. The filing includes weighted-average pricing and an undertaking to provide detail on per-price quantities upon request, reflecting transparency. There is no indication of amendments, unusual derivative activity, or changes in officer status in this filing. From a governance perspective, the disclosure aligns with Section 16 reporting requirements and shows procedural compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schneyer Mark C.

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S(1)		22,000	D	$25.1829(2)	40,130	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ACAD CFO Mark C. Schneyer sell according to the Form 4?

He sold 22,000 shares of Acadia Pharmaceuticals common stock on 08/18/2025.

At what price were the ACAD shares sold in the Form 4?

The filing reports a weighted-average price of $25.1829 and a price range of $25.06 to $25.28.

Were the sales by the reporting person part of a trading plan?

Yes. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025.

How many ACAD shares does the reporting person own after the sale?

The reporting person beneficially owned 40,130 shares following the reported transaction.

Who signed the Form 4 and when?

The Form 4 was signed by Jennifer J. Rhodes, Attorney-in-Fact on behalf of the reporting person on 08/19/2025.